ASH 2020 | ZUMA-5: high ORR and CR for R/R iNHL with axi-cel
David Maloney
• 15 Dec 2020
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, gives an update on the ongoing Phase II ZUMA-5 trial (NCT03105336) of axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR)-T cell therapy, for patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma and marginal zone lymphoma (MZL). Axi-cel has demonstrated a high overall response rate (ORR) at 92% and a high complete response (CR) rate at 76% in patients with iNHL at a median follow-up of 17.5 months. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
